1. Home
  2. MIRM vs KNSA Comparison

MIRM vs KNSA Comparison

Compare MIRM & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • KNSA
  • Stock Information
  • Founded
  • MIRM 2018
  • KNSA 2015
  • Country
  • MIRM United States
  • KNSA United Kingdom
  • Employees
  • MIRM N/A
  • KNSA N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • KNSA Biotechnology: Pharmaceutical Preparations
  • Sector
  • MIRM Health Care
  • KNSA Health Care
  • Exchange
  • MIRM Nasdaq
  • KNSA Nasdaq
  • Market Cap
  • MIRM 2.5B
  • KNSA 2.1B
  • IPO Year
  • MIRM 2019
  • KNSA 2018
  • Fundamental
  • Price
  • MIRM $52.17
  • KNSA $26.90
  • Analyst Decision
  • MIRM Strong Buy
  • KNSA Strong Buy
  • Analyst Count
  • MIRM 9
  • KNSA 6
  • Target Price
  • MIRM $66.22
  • KNSA $39.33
  • AVG Volume (30 Days)
  • MIRM 413.0K
  • KNSA 974.8K
  • Earning Date
  • MIRM 08-06-2025
  • KNSA 07-29-2025
  • Dividend Yield
  • MIRM N/A
  • KNSA N/A
  • EPS Growth
  • MIRM N/A
  • KNSA N/A
  • EPS
  • MIRM N/A
  • KNSA N/A
  • Revenue
  • MIRM $379,251,000.00
  • KNSA $481,166,000.00
  • Revenue This Year
  • MIRM $35.83
  • KNSA $37.21
  • Revenue Next Year
  • MIRM $16.83
  • KNSA $5.32
  • P/E Ratio
  • MIRM N/A
  • KNSA N/A
  • Revenue Growth
  • MIRM 69.31
  • KNSA 59.45
  • 52 Week Low
  • MIRM $36.20
  • KNSA $17.82
  • 52 Week High
  • MIRM $54.78
  • KNSA $30.69
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 56.47
  • KNSA 41.82
  • Support Level
  • MIRM $50.96
  • KNSA $28.19
  • Resistance Level
  • MIRM $53.59
  • KNSA $29.58
  • Average True Range (ATR)
  • MIRM 1.63
  • KNSA 0.93
  • MACD
  • MIRM -0.17
  • KNSA -0.19
  • Stochastic Oscillator
  • MIRM 53.06
  • KNSA 9.46

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Share on Social Networks: